# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 6, "Lancet", "", "<http://ctro/data#Publication_46459> <http://ctro/data#hasJournal> \"Lancet\"."
1, PublicationYear, 9, 13, "2013", "", "<http://ctro/data#Publication_46459> <http://ctro/data#hasPublicationYear> \"2013\"."
2, Linagliptin, 119, 130, "Linagliptin", "", 
25, Title, 119, 310, "Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments : a randomised , double - blind , placebo - controlled trial .", "", "<http://ctro/data#Publication_46459> <http://ctro/data#hasTitle> \"Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments : a randomised , double - blind , placebo - controlled trial .\"."
10, MinAge, 149, 157, "70 years", "", 
11, Type2Diabetes, 172, 187, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_46466> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
112, Precondition, 188, 247, "inadequately controlled with common antidiabetes treatments", "", "<http://ctro/data#Population_46482> <http://ctro/data#hasPrecondition> \"inadequately controlled with common antidiabetes treatments\"."
22, Randomized, 252, 262, "randomised", "", "<http://ctro/data#ClinicalTrial_46466> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
23, DoubleBlind, 265, 279, "double - blind", "", "<http://ctro/data#ClinicalTrial_46466> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
24, Placebo, 282, 289, "placebo", "", 
26, Author, 311, 321, "Barnett AH", "", "<http://ctro/data#Publication_46459> <http://ctro/data#hasAuthor> \"Barnett AH\"."
27, Author, 330, 339, "Huisman H", "", "<http://ctro/data#Publication_46459> <http://ctro/data#hasAuthor> \"Huisman H\"."
28, Author, 342, 349, "Jones R", "", "<http://ctro/data#Publication_46459> <http://ctro/data#hasAuthor> \"Jones R\"."
29, Author, 352, 366, "von Eynatten M", "", "<http://ctro/data#Publication_46459> <http://ctro/data#hasAuthor> \"von Eynatten M\"."
30, Author, 369, 376, "Patel S", "", "<http://ctro/data#Publication_46459> <http://ctro/data#hasAuthor> \"Patel S\"."
31, Author, 379, 388, "Woerle HJ", "", "<http://ctro/data#Publication_46459> <http://ctro/data#hasAuthor> \"Woerle HJ\"."
32, UK, 534, 536, "UK", "", "<http://ctro/data#Population_46482> <http://ctro/data#hasCountry> <http://ctro/data#UK>."
12, Type2Diabetes, 907, 922, "type 2 diabetes", "", 
67287, MinAge, 939, 947, "65 years", "", 
21, ObjectiveDescription, 1043, 1178, "We aimed to assess the effectiveness of linagliptin , a dipeptidyl peptidase - 4 inhibitor , in elderly patients with type 2 diabetes .", "", "<http://ctro/data#ClinicalTrial_46466> <http://ctro/data#hasObjectiveDescription> \"We aimed to assess the effectiveness of linagliptin , a dipeptidyl peptidase - 4 inhibitor , in elderly patients with type 2 diabetes .\"."
3, Linagliptin, 1083, 1094, "linagliptin", "", 
125, Precondition, 1139, 1176, "elderly patients with type 2 diabetes", "", 
13, Type2Diabetes, 1161, 1176, "type 2 diabetes", "", 
33, Randomized, 1197, 1207, "randomised", "", 
34, DoubleBlind, 1210, 1224, "double - blind", "", 
35, Parallel, 1227, 1243, "parallel - group", "", "<http://ctro/data#ClinicalTrial_46466> <http://ctro/data#hasCTDesign> <http://ctro/data#Parallel>."
36, Multicenter, 1246, 1259, "multinational", "", "<http://ctro/data#ClinicalTrial_46466> <http://ctro/data#hasCTDesign> <http://ctro/data#Multicenter>."
67378, Precondition, 1276, 1474, "patients aged 70 years or older with type 2 diabetes , glycated haemoglobin A1c ( HbA1c ) of 7 · 0 % or more , receiving metformin , sulfonylureas , or basal insulin , or combinations of these drugs", "", "<http://ctro/data#Population_46482> <http://ctro/data#hasPrecondition> \"patients aged 70 years or older with type 2 diabetes , glycated haemoglobin A1c ( HbA1c ) of 7 · 0 % or more , receiving metformin , sulfonylureas , or basal insulin , or combinations of these drugs\"."
19, MinAge, 1290, 1298, "70 years", "", 
14, Type2Diabetes, 1313, 1328, "type 2 diabetes", "", 
37, HbA1c, 1331, 1355, "glycated haemoglobin A1c", "", 
38, HbA1c, 1358, 1363, "HbA1c", "", 
39, Percentage, 1375, 1376, "%", "", 
40, Metformin, 1397, 1406, "metformin", "", 
41, Sulfonylureas, 1409, 1422, "sulfonylureas", "", 
67375, Insulin, 1434, 1441, "insulin", "", 
43, Randomized, 1482, 1492, "randomised", "", 
145, Randomized, 1519, 1532, "randomisation", "", 
45, HbA1c, 1601, 1606, "HbA1c", "", 
46, Percentage, 1623, 1624, "%", "", 
47, Percentage, 1636, 1637, "%", "", 
67377, Insulin, 1644, 1651, "insulin", "", 
48, AllocationRatio, 1695, 1700, "2 : 1", "", "<http://ctro/data#AllocationRatio_46470> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#AllocationRatio>. <http://ctro/data#ClinicalTrial_46466> <http://ctro/data#hasAllocationRatio> <http://ctro/data#AllocationRatio_46470>."
49, Frequency, 1710, 1722, "once - daily", "", "<http://ctro/data#Intervention_46525> <http://ctro/data#hasFrequency> \"once - daily\". <http://ctro/data#Intervention_46531> <http://ctro/data#hasFrequency> \"once - daily\"."
50, Oral, 1723, 1727, "oral", "", "<http://ctro/data#Medication_46490> <http://ctro/data#hasDeliveryMethod> <http://ctro/data#Oral>."
4, Linagliptin, 1743, 1754, "linagliptin", "", "<http://ctro/data#Medication_46490> <http://ctro/data#hasDrug> <http://ctro/data#Linagliptin>."
51, DoseValue, 1755, 1756, "5", "", "<http://ctro/data#Medication_46490> <http://ctro/data#hasDoseValue> \"5\"."
52, mg, 1757, 1759, "mg", "", "<http://ctro/data#Medication_46490> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
53, Placebo, 1772, 1779, "placebo", "", "<http://ctro/data#Medication_46490> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
54, Duration, 1784, 1792, "24 weeks", "", "<http://ctro/data#ClinicalTrial_46466> <http://ctro/data#hasCTduration> \"24 weeks\"."
153, DoubleBlind, 1795, 1837, "Investigators and participants were masked", "", 
55, HbA1c, 1910, 1915, "HbA1c", "", 
56, TimePoint, 1921, 1929, "baseline", "", 
57, TimePoint, 1933, 1940, "week 24", "", 
59, NumberPatientsCT, 2028, 2031, "241", "", "<http://ctro/data#ClinicalTrial_46466> <http://ctro/data#hasNumberPatientsCT> \"241\"."
60, Randomized, 2068, 2078, "randomised", "", 
61, NumberPatientsArm, 2081, 2084, "162", "", "<http://ctro/data#Arm_46555> <http://ctro/data#hasNumberPatientsArm> \"162\"."
63, Linagliptin, 2085, 2096, "linagliptin", "", 
62, NumberPatientsArm, 2099, 2101, "79", "", "<http://ctro/data#Arm_46568> <http://ctro/data#hasNumberPatientsArm> \"79\"."
65, Placebo, 2102, 2109, "placebo", "", 
163, Mean, 2114, 2118, "Mean", "", 
162, AvgAge, 2127, 2139, "74 · 9 years", "", "<http://ctro/data#Population_46482> <http://ctro/data#hasAvgAge> \"74 · 9 years\"."
164, Mean, 2155, 2159, "Mean", "", 
69, HbA1c, 2160, 2165, "HbA1c", "", 
70, BaseLineValue, 2170, 2175, "7 · 8", "", "<http://ctro/data#Outcome_46596> <http://ctro/data#hasBaselineValue> \"7 · 8\"."
71, Percentage, 2176, 2177, "%", "", 
72, SdDevBL, 2183, 2188, "0 · 8", "", "<http://ctro/data#Outcome_46596> <http://ctro/data#hasSdDevBL> \"0 · 8\"."
58, TimePoint, 2196, 2203, "week 24", "", "<http://ctro/data#Outcome_46596> <http://ctro/data#hasTimePoint> \"week 24\"."
67, Placebo, 2206, 2213, "placebo", "", 
171, Mean, 2225, 2229, "mean", "", "<http://ctro/data#Mean_46593> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#Mean>. <http://ctro/data#Endpoint_46591> <http://ctro/data#hasAggregationMethod> <http://ctro/data#Mean_46593>."
73, HbA1c, 2240, 2245, "HbA1c", "", "<http://ctro/data#Endpoint_46591> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
5, Linagliptin, 2251, 2262, "linagliptin", "", 
74, Reduction, 2269, 2275, "0 · 64", "", "<http://ctro/data#Outcome_46596> <http://ctro/data#hasChangeValue> \"0 · 64\"."
75, Percentage, 2276, 2277, "%", "", "<http://ctro/data#Endpoint_46591> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
76, ConfIntervalChangeValue, 2280, 2308, "95 % CI - 0 · 81 to - 0 · 48", "", "<http://ctro/data#Outcome_46596> <http://ctro/data#hasConfIntervalChangeValue> \"95 % CI - 0 · 81 to - 0 · 48\"."
77, PValueChangeValue, 2311, 2323, "p < 0 · 0001", "", "<http://ctro/data#Outcome_46596> <http://ctro/data#hasPValueChangeValue> \"p < 0 · 0001\"."
6, Linagliptin, 2391, 2402, "linagliptin", "", 
66, Placebo, 2407, 2414, "placebo", "", 
78, PercentageAffected, 2424, 2430, "75 · 9", "", "<http://ctro/data#Outcome_46628> <http://ctro/data#hasPercentageAffected> \"75 · 9\". <http://ctro/data#Outcome_46655> <http://ctro/data#hasPercentageAffected> \"75 · 9\"."
79, EndPointDescription, 2464, 2480, "an adverse event", "", "<http://ctro/data#EndPointDescription_46624> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_46623> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_46624>."
7, Linagliptin, 2483, 2494, "linagliptin", "", 
80, NumberAffected, 2499, 2502, "123", "", "<http://ctro/data#Outcome_46628> <http://ctro/data#hasNumberAffected> \"123\"."
82, Placebo, 2505, 2512, "placebo", "", 
81, NumberAffected, 2517, 2519, "60", "", "<http://ctro/data#Outcome_46655> <http://ctro/data#hasNumberAffected> \"60\"."
84, EndPointDescription, 2545, 2567, "Serious adverse events", "", "<http://ctro/data#EndPointDescription_46683> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_46682> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_46683>."
85, PercentageAffected, 2580, 2585, "8 · 6", "", "<http://ctro/data#Outcome_46687> <http://ctro/data#hasPercentageAffected> \"8 · 6\"."
87, NumberAffected, 2590, 2592, "14", "", "<http://ctro/data#Outcome_46687> <http://ctro/data#hasNumberAffected> \"14\"."
64, Linagliptin, 2614, 2625, "linagliptin", "", 
86, PercentageAffected, 2636, 2641, "6 · 3", "", "<http://ctro/data#Outcome_46714> <http://ctro/data#hasPercentageAffected> \"6 · 3\"."
88, NumberAffected, 2646, 2650, "five", "", "<http://ctro/data#Outcome_46714> <http://ctro/data#hasNumberAffected> \"five\"."
89, Placebo, 2669, 2676, "placebo", "", 
90, ObservedResult, 2685, 2723, "none were deemed related to study drug", "", "<http://ctro/data#Outcome_46687> <http://ctro/data#hasObservedResult> \"none were deemed related to study drug\"."
91, Hypoglycemia, 2726, 2739, "Hypoglycaemia", "", "<http://ctro/data#Endpoint_46742> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Hypoglycemia>."
93, PercentageAffected, 2827, 2833, "24 · 1", "", "<http://ctro/data#Outcome_46747> <http://ctro/data#hasPercentageAffected> \"24 · 1\"."
95, NumberAffected, 2838, 2840, "39", "", "<http://ctro/data#Outcome_46747> <http://ctro/data#hasNumberAffected> \"39\"."
8, Linagliptin, 2850, 2861, "linagliptin", "", 
94, PercentageAffected, 2870, 2876, "16 · 5", "", "<http://ctro/data#Outcome_46774> <http://ctro/data#hasPercentageAffected> \"16 · 5\"."
96, NumberAffected, 2881, 2883, "13", "", "<http://ctro/data#Outcome_46774> <http://ctro/data#hasNumberAffected> \"13\"."
97, Placebo, 2893, 2900, "placebo", "", 
98, ConfIntervalDiff, 2929, 2952, "95 % CI 0 · 78 - 3 · 78", "", "<http://ctro/data#DiffBetweenGroups_46801> <http://ctro/data#hasConfIntervalDiff> \"95 % CI 0 · 78 - 3 · 78\"."
99, PvalueDiff, 2955, 2967, "p = 0 · 2083", "", "<http://ctro/data#DiffBetweenGroups_46801> <http://ctro/data#hasPvalueDiff> \"p = 0 · 2083\"."
101, ConclusionComment, 2989, 3120, "In elderly patients with type 2 diabetes linagliptin was efficacious in lowering glucose with a safety profile similar to placebo .", "", "<http://ctro/data#ClinicalTrial_46466> <http://ctro/data#hasConclusionComment> \"In elderly patients with type 2 diabetes linagliptin was efficacious in lowering glucose with a safety profile similar to placebo .\"."
15, Type2Diabetes, 3014, 3029, "type 2 diabetes", "", 
9, Linagliptin, 3030, 3041, "linagliptin", "", 
100, Placebo, 3111, 3118, "placebo", "", 
102, ConclusionComment, 3121, 3274, "These findings could inform treatment decisions for achieving individualised glycaemic goals with minimal risk in this important population of patients .", "", "<http://ctro/data#ClinicalTrial_46466> <http://ctro/data#hasConclusionComment> \"These findings could inform treatment decisions for achieving individualised glycaemic goals with minimal risk in this important population of patients .\"."
106321, PharmacySponsored, 3285, 3305, "Boehringer Ingelheim", "", "<http://ctro/data#EvidenceQuality_92007> <http://ctro/data#isPharmacySponsored> \"Boehringer Ingelheim\"."
103, PMID, 3417, 3425, "23948125", "", "<http://ctro/data#Publication_46459> <http://ctro/data#hasPMID> \"23948125\"."
